---
title: "AbbVie Declares Quarterly Dividend | ABBV Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298632359.md"
description: "AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $1.73 per share, payable on November 16, 2026, to shareholders of record as of October 15, 2026. Since its inception in 2013, AbbVie has increased its dividend by over 330 percent and is a member of the S&P Dividend Aristocrats Index."
datetime: "2026-09-10T10:17:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298632359.md)
  - [en](https://longbridge.com/en/news/298632359.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298632359.md)
generator: "portal-rs"
---

# AbbVie Declares Quarterly Dividend | ABBV Stock News

AbbVie (ABBV) declared a quarterly cash dividend of $1.73 per share, payable on November 16, 2026, to shareholders of record as of October 15, 2026.

, /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. 

The cash dividend is payable November 16, 2026, to stockholders of record at the close of business on October 15, 2026.

Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

**About AbbVie**

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

**Media:** 

**Investors:**

Catherine Langel

Liz Shea

(708) 508-3524 

(847) 935-2211

catherine.langel@abbvie.com

liz.shea@abbvie.com

SOURCE AbbVie

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [AbbVie says FDA grants breakthrough therapy status for ABBV-400 in metastatic colorectal cancer](https://longbridge.com/en/news/301144773.md)
- [AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo | ABBV Stock News](https://longbridge.com/en/news/300695604.md)
- [AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates](https://longbridge.com/en/news/300591646.md)
- [AbbVie wins EU approval for paediatric pJIA use](https://longbridge.com/en/news/300559910.md)
- [BUZZ-Genmab at 3-year high after blood cancer drug combination study results](https://longbridge.com/en/news/301001061.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**